EUVIMEDScopri EUVIMED
Open access · CC BY 4.0

Cannabis Use and Clinical Outcomes in First Episode Psychosis: Results From a 2‐Year Follow‐Up Study

Ilaria Domenicano, Alice Onofrio, Domenico De Donatis, Sara Malservigi, Giuseppe Di Vincenzo, Martino Belvederi Murri, Luigi Grassi, Maria Ferrara iD

Early Intervention in Psychiatry · 2026-05 · 20 (5)

DOI: 10.1111/eip.70179 ↗

At a glance

Journal article in Early Intervention in Psychiatry, published online on 2026-05-16. Written by Ilaria Domenicano and 7 co-authors. Institution: Institute of Psychiatry, Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy. Major MEDLINE topics: Psychotic Disorders, Antipsychotic Agents, Marijuana Use. Cited 2 times so far (Crossref); 55 references. The full text is freely available (open access, CC BY 4.0). Funded by: Ministero dell'Università e della Ricerca.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Aim

This study aimed to investigate the association between cannabis use prior to enrollment in a First Episode Psychosis (FEP) program and prognosis, including severity of psychiatric symptoms, type of antipsychotic treatment prescribed, and clinical recovery.

Methods

A longitudinal cohort study was conducted on patients aged 18–35 diagnosed with affective and non‐affective psychosis who were referred to the FEP Program in Ferrara, Italy, between 2012 and April 2024. Sociodemographic and clinical data were collected at program entry and every six months for up to 24 months. Cannabis use was categorised dichotomously based on reported or charted use within the month prior to program entry. The Health of the Nation Outcome Scale (HoNOS) was used to monitor clinical outcomes (assessed through reductions of the total HoNOS score, employment status, and type of antipsychotic prescription) and recovery (total HoNOS < 8). Bivariate analyses compared sociodemographic characteristics and clinical outcomes between people with cannabis use and people without cannabis use at baseline and at 1‐ and 2‐year follow‐ups, considering both baseline cannabis status and current cannabis use status. A Mixed Model for Repeated Measures, was used to compare the average HoNOS scores and the recovery rates between the two groups at several endpoints (baseline, 12 months and 24 months).

Results

The total sample included 173 patients, predominantly men (74.5%), diagnosed with non‐affective psychosis (83.8%), with a median age at onset of psychotic symptoms of 22.9 years. At admission, individuals reporting cannabis use (48%), compared to those without cannabis use, were predominantly male (87.9% vs. 62.2%, p < 0.001), had a significantly shorter duration of untreated psychosis (32.8 vs. 52.2 weeks, p = 0.05) and were more likely to receive combined oral and depot antipsychotic treatment (16.9% vs. 5.6%, p = 0.05), no difference in baseline HoNOS scores was observed. At 1‐ and 2‐year follow‐ups, no significant differences in overall psychopathology were found between groups under either cannabis use condition. However, baseline cannabis exposure was associated with lower rates of student status at both 1‐year (11.8% vs. 24.3%) and 2‐year (6.3% vs. 23.2%) follow‐ups. At the 1‐year follow‐up, participants with cannabis use were more likely to receive a combination of long‐acting injectable (LAI) and oral antipsychotics (21.1% vs. 7.3%, p = 0.05) compared to those without cannabis use. No significant differences were found between the two groups in terms of HoNOS scores or recovery rates at any time point (baseline, 12 months, 24 months).

Conclusions

Cannabis use prior to FEP program entry was not associated with significant differences in clinical outcomes or recovery, despite being admitted with a shorter DUP and being predominantly male. Nevertheless, cannabis use was associated with more intensive antipsychotic treatment, both at admission and at 1 year. These findings underscore the importance of early detection of cannabis use and integrated care addressing both psychiatric symptoms and substance use. Future randomised controlled trials should explore whether reducing cannabis use can decrease antipsychotic burden and improve long‐term outcomes.

Subjects

MeSH terms (MEDLINE)

Psychotic DisordersAntipsychotic AgentsMarijuana UseHumansMaleAdultFemaleFollow-Up StudiesYoung AdultAdolescentLongitudinal StudiesItaly

Author keywords

cannabis useclinical outcomesfirst episode psychosisrecoveryuntreated psychosis

Substances

Antipsychotic Agents

Authors and institutions

  • Institute of Psychiatry, Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy.
  • Integrated Department of Mental Health and Pathological Addictions, Ferrara Health Trust, Ferrara, Italy.
  • Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut, USA.

ORCID profiles: Maria Ferrara

Funding

  • Ministero dell'Università e della Ricerca

Cite

APA

Domenicano, I., Onofrio, A., De Donatis, D., Malservigi, S., Di Vincenzo, G., Murri, M. B., Grassi, L., & Ferrara, M. (2026). Cannabis Use and Clinical Outcomes in First Episode Psychosis: Results From a 2‐Year Follow‐Up Study. Early Intervention in Psychiatry, 20(5). https://doi.org/10.1111/eip.70179

Vancouver

Domenicano I, Onofrio A, De Donatis D, Malservigi S, Di Vincenzo G, Murri MB, et al. Cannabis Use and Clinical Outcomes in First Episode Psychosis: Results From a 2‐Year Follow‐Up Study. Early Intervention in Psychiatry. 2026;20(5). doi:10.1111/eip.70179

BibTeX
@article{Domenicano2026,
  author = {Domenicano, Ilaria and Onofrio, Alice and De Donatis, Domenico and Malservigi, Sara and Di Vincenzo, Giuseppe and Murri, Martino Belvederi and Grassi, Luigi and Ferrara, Maria},
  title = {Cannabis Use and Clinical Outcomes in First Episode Psychosis: Results From a 2‐Year Follow‐Up Study},
  journal = {Early Intervention in Psychiatry},
  year = {2026},
  volume = {20},
  number = {5},
  doi = {10.1111/eip.70179}
}
Start for free →